Dr. Sebastian Thams is a resident in neurology at Karolinska university hospital with focus on ALS and neuromuscular disorders. He has 10+ years of experience in basic and translational research, including a 4 year postdoc period at Columbia University motor neuron center, where he worked on small molecule screening and development of new drug candidates in ALS. Dr. Thams’ current research focuses on disease mechanisms and drug discovery in iPS-derived motor neurons from ALS patients with familial disease.
Connect
Connect trials
PHOENIX trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
ADORE Trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
COURAGE-ALS Trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
APL2-ALS-206 Trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
TUDCA-ALS
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.